## We Claim:

1. Aldose reductase inhibitor of the formula I or a pharmaceutically acceptable derivative thereof.

- 2. An acid or base addition product of the compound of claim 1
- 3. A pharmaceutical preparation containing an effective amount of the compound of Claim 1 and one or more pharmaceutically acceptable excipients.
- 4. Aldose reductase inhibitor as claimed in claim 1 wherein said inhibitor is a rat lens aldose reductase inhibitor.
- 5. Aldose reductase inhibitor as claimed in claim 1 wherein the aldose reductase inhibitor of formula I is 2, 6, dihydroxy, 8, hexoxy, 1, 4, naphthaquinone.
- 6. A process for the isolation of a novel aldose reductase inhibitor of the formula I below

HO 
$$\frac{O}{2}$$
  $\frac{O}{10}$   $\frac{12}{13}$   $\frac{14}{15}$   $\frac{16}{CH_3}$   $\frac{16}{CH_3}$   $O$ 

1

the process comprising culturing Aspergillus niger CFR 1046 and isolating said aldose reductase inhibitor.

- 7. A process as claimed in claim 6 wherein the aldose reductase inhibitor isolated from Aspergillus niger CFR 1046 is 2, 6, dihydroxy, 8, hexoxy, 1, 4, naphthaquinone.
- 8. A process as claimed in claim 6 wherein the aldose reductase inhibitory compound of formula I is isolated from Aspergillus niger CFR 1046 by fermentation.
- 9. A process as claimed in claim 6 wherein naphthaquinone is isolated from fermentates of Aspergillus niger CFR 1046 by solvent extraction.